T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, Jennifer J.D. Morrissette et al.|Nature Medicine|2024Cited by 254
Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myelomaBeatrice M. Razzo, Alfred L. Garfall, Rajshekhar Chakraborty et al.|Blood|2025Cited by 6